Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.43 |
| ▸ | PRKACA | P17612 | 3/20 | 0.42 |
| ▸ | PRKACG | P22612 | 3/20 | 0.42 |
| ▸ | PRKACB | P22694 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780356 | 0.88 | PDGFRB (0.56) | ROCK2PDGFRBPDGFRAROCK1 | |
| SCHEMBL782152 | 0.87 | ROCK2 (0.55) | ROCK2PDGFRBPDGFRAROCK1 | |
| SCHEMBL780371 | 0.87 | ROCK2 (0.51) | ROCK2PDGFRBPDGFRAPRKACAPRKACG | |
| SCHEMBL780558 | 0.87 | ROCK2 (0.51) | ROCK2PDGFRBPDGFRAROCK1PRKACA | |
| Hydrochloric Acid SCHEMBL16161764 | 0.86 | ROCK2 (0.54) | ROCK2PDGFRBPDGFRAROCK1 | |
| SCHEMBL781911 | 0.85 | ROCK2 (0.56) | ROCK2PDGFRBPDGFRAROCK1PRKACA | |
| SCHEMBL781535 | 0.84 | TPH1 (0.44) | ROCK2PDGFRBPDGFRAROCK1PRKACA | |
| SCHEMBL781892 | 0.84 | CLK4 (0.48) | PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL16161703 | 0.83 | CLK4 (0.48) | PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL16162192 | 0.83 | TPH1 (0.43) | ROCK2PDGFRBPDGFRAROCK1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | claimed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | claimed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | claimed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | claimed |
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | CDK1, CDK2, CDK6 | ROCK2 733/4885PDGFRB 1860/4885PDGFRA 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.